Description
Thymosin Alpha-1 (TA1) is a synthetic version of a naturally occurring thymic peptide fragment. It is studied for its role in immune system modulation, host defense, and inflammation balance, with applications in viral immunity, cancer research, and vaccine adjuvant studies.
Benefits
- Immune modulation — studied for enhancing T-cell differentiation and activity.
- Host defense — explored in viral, bacterial, and fungal infection research.
- Cancer research — linked to improved immune surveillance and checkpoint synergy.
- Inflammation balance — studied for calming excess inflammatory responses.
- Vaccine support — explored as an immune adjuvant in vaccine trials.
What researchers look at
- Mechanism: activates TLRs, dendritic cells, and enhances T-cell function.
- Clinical trials in viral hepatitis, influenza, HIV, and cancer immunotherapy.
- Synergy with checkpoint inhibitors and other immunotherapies.
- Exploration as an adjuvant in vaccine development.
Quick Specs
- Form: Lyophilized peptide
- Net per vial: 10 mg
- Purity: ≥99% (HPLC)
- Identity: MS-verified (per COA)
- Storage: 2–8 °C, protect from light
Identity Basics
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
- Formula / M.W.: C129H215N33O55, ~3108 g/mol
- CAS: 62304-98-7
Selected Research
- PubChem entry — chemical identity:
https://pubchem.ncbi.nlm.nih.gov/compound/16132395
- Immune modulation and T-cell activation:
https://pubmed.ncbi.nlm.nih.gov/30626024/
- Viral infection studies (hepatitis, influenza):
https://pubmed.ncbi.nlm.nih.gov/20235459/
- Cancer immunotherapy synergy:
https://pubmed.ncbi.nlm.nih.gov/31058686/
- Vaccine adjuvant trials:
https://pubmed.ncbi.nlm.nih.gov/33333290/
⚠️ Disclaimer
-
This product is intended for laboratory research use only.
-
Not for human or veterinary use.
-
Not approved for diagnostic, therapeutic, or medical applications.
-
Handle using appropriate laboratory safety procedures and personal protective equipment.
